Browsing by Author "Huang, M"

Now showing 1 - 3 of 3
  • Thumbnail Image
    ItemOpen Access
    Autonomic and electrocardiographic findings in Parkinson’s disease
    (Autonomic Neuroscience, 2017) Gibbons, CH; Simon, DK; Huang, M; Tilley, B; Aminoff, MJ; Bainbridge, JL; Brodsky, M; Freeman, R; Goudreau, J; Hamill, RW; Luo, S; Singer, C; Videnovic, A; Bodis-Wollner, I; Wong, PS
  • Thumbnail Image
    ItemOpen Access
    Changes in Medical Therapy and Lifestyle After Anatomical Versus Functional Testing for Coronary Artery Disease: The PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)
    (CIRCULATION, 2015-11-10) Ladapo, JA; Hoffman, U; Lee, KL; Coles, AL; Huang, M; Mark, DB; Dolor, RL; Pelberg, RA; Budoff, M; Sigurdsson, G; Severance, HW; Douglas, PS
    Introduction: Diagnostic testing may represent a “teachable moment” for patients newly presenting with symptoms suggestive of CAD and requiring further evaluation, and may influence risk factor management, independent of test results. However, little is known about changes in medications and lifestyle after anatomical versus functional testing. Hypothesis: Patients assigned to coronary CTA will report greater use of preventive medications and lifestyle practices. Methods: We randomly assigned 10,003 symptomatic patients (53% women; mean age 61 yrs) to anatomical testing with CTA or functional testing (exercise ECG, nuclear stress, or stress echocardiography). We assessed use of preventive medications (aspirin, statin, beta blocker, and ACEi/ARB) and lifestyle practices (heart healthy diet, regular exercise, smoking, and obese/overweight status [BMI>25]) at 60 days. Chi-square tests assessed between-group changes (initiation or discontinuation). Multivariable logistic regression models assessed the association between testing strategy and prevalence of medication use or lifestyle practices. Results: There were no differences in medications or lifestyle practices at baseline. At 60 days, the CTA strategy was associated with a higher proportion of patients newly initiating aspirin (11.6% vs 7.6%), statin (12.7% vs 6.2%), and beta blockers (8.2% vs 5.4%), compared to functional testing (p<0.0001 for each). The CTA strategy was also associated with a higher incidence of weight loss among obese/overweight patients (2.8% vs 2.4%), but the difference was not significant (p=0.051). Overall prevalences of aspirin (aOR=1.55), statin (aOR=2.04), and beta blocker (aOR=1.32) use were higher after CTA (p<0.001 for each). Eating a healthy diet (54.7% vs 50.8%) was increased after CTA (aOR=1.13 p=0.004), whereas obese/overweight status was reduced (aOR=0.79 p=0.047). Exercise and smoking cessation increased similarly in both arms. Benefits of CTA for statin use and weight loss persisted after adjusting for test results. Conclusions: Among patients with suspected CAD, anatomical testing is associated with greater favorable changes in preventive medical and lifestyle practices. This may represent a long term benefit of a CTA testing strategy.
  • Thumbnail Image
    ItemOpen Access
    Electron-Ion Collider: The next QCD frontier: Understanding the glue that binds us all
    (European Physical Journal A, 2016-09-01) Accardi, A; Albacete, JL; Anselmino, M; Armesto, N; Aschenauer, EC; Bacchetta, A; Boer, D; Brooks, WK; Burton, T; Chang, NB; Deng, WT; Deshpande, A; Diehl, M; Dumitru, A; Dupré, R; Ent, R; Fazio, S; Gao, H; Guzey, V; Hakobyan, H; Hao, Y; Hasch, D; Holt, R; Horn, T; Huang, M; Hutton, A; Hyde, C; Jalilian-Marian, J; Klein, S; Kopeliovich, B; Kovchegov, Y; Kumar, K; Kumerički, K; Lamont, MAC; Lappi, T; Lee, JH; Lee, Y; Levin, EM; Lin, FL; Litvinenko, V; Ludlam, TW; Marquet, C; Meziani, ZE; McKeown, R; Metz, A; Milner, R; Morozov, VS; Mueller, AH; Müller, B; Müller, D; Nadel-Turonski, P; Paukkunen, H; Prokudin, A; Ptitsyn, V; Qian, X; Qiu, JW; Ramsey-Musolf, M; Roser, T; Sabatié, F; Sassot, R; Schnell, G; Schweitzer, P; Sichtermann, E; Stratmann, M; Strikman, M; Sullivan, M; Taneja, S; Toll, T; Trbojevic, D; Ullrich, T; Venugopalan, R; Vigdor, S; Vogelsang, W; Weiss, C; Xiao, BW; Yuan, F; Zhang, YH; Zheng, L
    © 2016, The Author(s). This White Paper presents the science case of an Electron-Ion Collider (EIC), focused on the structure and interactions of gluon-dominated matter, with the intent to articulate it to the broader nuclear science community. It was commissioned by the managements of Brookhaven National Laboratory (BNL) and Thomas Jefferson National Accelerator Facility (JLab) with the objective of presenting a summary of scientific opportunities and goals of the EIC as a follow-up to the 2007 NSAC Long Range plan. This document is a culmination of a community-wide effort in nuclear science following a series of workshops on EIC physics over the past decades and, in particular, the focused ten-week program on “Gluons and quark sea at high energies” at the Institute for Nuclear Theory in Fall 2010. It contains a brief description of a few golden physics measurements along with accelerator and detector concepts required to achieve them. It has been benefited profoundly from inputs by the users’ communities of BNL and JLab. This White Paper offers the promise to propel the QCD science program in the US, established with the CEBAF accelerator at JLab and the RHIC collider at BNL, to the next QCD frontier.